Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 53-14 PYTHIA 

A Phase II Study of Palbociclib plus Fulvestrant versus Placebo plus Fulvestrant for pretreated patients with ER+/HER2-Metastatic Breast Cancer.

Palbociclib in molecularly characterized ER-positive/HER2-negative metastatic breast cancer: the PYTHIA study.

DESIGN

please click on the picture to see a larger version

Study Chair
Dr. Luca Malorni (Prato, Italy)

Statistician
Meredith Regan, ScD

Lead Trial Coordinator
Holly Shaw

Trial Coordinator
Poonam Jani

Data Managers
Adriana Mora de Karausch, Monica Greco

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email: ibcsg53_pythia@fstrf.org

Trial Monitors
Daniela Celotto, Carmen Comune

IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email: pythia-monitoring@ibcsg.org

Date of Activation
August 28, 2015

Targeted Accrual
120


News

23.03.2019:
The next IBCSG Annual Meeting will take place in Vienna Austria on March 23 and 24, 2019.       

17.09.2018:
New publications are available 

17.09.2018:
Clinical Trials

All News

 
  Print